Comparative Pharmacology
Head-to-head clinical analysis: KALEXATE versus PROZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KALEXATE versus PROZAC.
KALEXATE vs PROZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
10 mg orally once daily.
20 mg orally once daily, initially; may increase to 40 mg once daily after several weeks; maximum 80 mg once daily.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Fluoxetine: 4-6 days; norfluoxetine: 4-16 days; extensive accumulation with chronic dosing, steady-state in 4-5 weeks
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Renal: ~80% (primarily as metabolites, <10% unchanged); fecal: ~15%
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant